These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 23178165)

  • 1. Amylin exerts osteogenic actions with different efficacy depending on the diabetic status.
    Gutiérrez-Rojas I; Lozano D; Nuche-Berenguer B; Moreno P; Acitores A; Ramos-Álvarez I; Rovira A; Novials A; Martín-Crespo E; Villanueva-Peñacarrillo ML; Esbrit P
    Mol Cell Endocrinol; 2013 Jan; 365(2):309-15. PubMed ID: 23178165
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exendin-4 exerts osteogenic actions in insulin-resistant and type 2 diabetic states.
    Nuche-Berenguer B; Moreno P; Portal-Nuñez S; Dapía S; Esbrit P; Villanueva-Peñacarrillo ML
    Regul Pept; 2010 Jan; 159(1-3):61-6. PubMed ID: 19586609
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of GLP-1 treatment on bone turnover in normal, type 2 diabetic, and insulin-resistant states.
    Nuche-Berenguer B; Moreno P; Esbrit P; Dapía S; Caeiro JR; Cancelas J; Haro-Mora JJ; Villanueva-Peñacarrillo ML
    Calcif Tissue Int; 2009 Jun; 84(6):453-61. PubMed ID: 19219381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amylin increases bone volume but cannot ameliorate diabetic osteopenia.
    Romero DF; Bryer HP; Rucinski B; Isserow JA; Buchinsky FJ; Cvetkovic M; Liu CC; Epstein S
    Calcif Tissue Int; 1995 Jan; 56(1):54-61. PubMed ID: 7796348
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anabolic Effect of Insulin Therapy on the Bone: Osteoprotegerin and Osteocalcin Up-Regulation in Streptozotocin-Induced Diabetic Rats.
    Bortolin RH; Freire Neto FP; Arcaro CA; Bezerra JF; da Silva FS; Ururahy MA; Souza KS; Lima VM; Luchessi AD; Lima FP; Lia Fook MV; da Silva BJ; Almeida MD; Abreu BJ; de Rezende LA; de Rezende AA
    Basic Clin Pharmacol Toxicol; 2017 Mar; 120(3):227-234. PubMed ID: 27651300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Amylin and bone metabolism in streptozotocin-induced diabetic rats.
    Horcajada-Molteni MN; Chanteranne B; Lebecque P; Davicco MJ; Coxam V; Young A; Barlet JP
    J Bone Miner Res; 2001 May; 16(5):958-65. PubMed ID: 11341342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protection against T1DM-Induced Bone Loss by Zinc Supplementation: Biomechanical, Histomorphometric, and Molecular Analyses in STZ-Induced Diabetic Rats.
    Bortolin RH; da Graça Azevedo Abreu BJ; Abbott Galvão Ururahy M; Costa de Souza KS; Bezerra JF; Loureiro MB; da Silva FS; Marques DE; Batista AA; Oliveira G; Luchessi AD; Lima VM; Miranda CE; Lia Fook MV; Almeida Md; de Rezende LA; de Rezende AA
    PLoS One; 2015; 10(5):e0125349. PubMed ID: 25933189
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amylin effect in extrapancreatic tissues participating in glucose homeostasis, in normal, insulin-resistant and type 2 diabetic state.
    Moreno P; Acitores A; Gutiérrez-Rojas I; Nuche-Berenguer B; El Assar M; Rodriguez-Mañas L; Gomis R; Valverde I; Visa M; Malaisse WJ; Novials A; González N; Villanueva-Peñacarrillo ML
    Peptides; 2011 Oct; 32(10):2077-85. PubMed ID: 21939703
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anabolic action of parathyroid hormone is skeletal site specific at the tissue and cellular levels in mice.
    Iida-Klein A; Zhou H; Lu SS; Levine LR; Ducayen-Knowles M; Dempster DW; Nieves J; Lindsay R
    J Bone Miner Res; 2002 May; 17(5):808-16. PubMed ID: 12009011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparative study of the bone metabolic response to dried plum supplementation and PTH treatment in adult, osteopenic ovariectomized rat.
    Smith BJ; Bu SY; Wang Y; Rendina E; Lim YF; Marlow D; Clarke SL; Cullen DM; Lucas EA
    Bone; 2014 Jan; 58():151-9. PubMed ID: 24125756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Formononetin reverses established osteopenia in adult ovariectomized rats.
    Tyagi AM; Srivastava K; Singh AK; Kumar A; Changkija B; Pandey R; Lahiri S; Nagar GK; Yadav DK; Maurya R; Trivedi R; Singh D
    Menopause; 2012 Aug; 19(8):856-63. PubMed ID: 22781783
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of RANKL/OPG during bone remodeling in vivo.
    Tanaka H; Mine T; Ogasa H; Taguchi T; Liang CT
    Biochem Biophys Res Commun; 2011 Aug; 411(4):690-4. PubMed ID: 21771583
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Catabolic effects of continuous human PTH (1--38) in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation.
    Ma YL; Cain RL; Halladay DL; Yang X; Zeng Q; Miles RR; Chandrasekhar S; Martin TJ; Onyia JE
    Endocrinology; 2001 Sep; 142(9):4047-54. PubMed ID: 11517184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GLP-1 and exendin-4 can reverse hyperlipidic-related osteopenia.
    Nuche-Berenguer B; Lozano D; Gutiérrez-Rojas I; Moreno P; Mariñoso ML; Esbrit P; Villanueva-Peñacarrillo ML
    J Endocrinol; 2011 May; 209(2):203-10. PubMed ID: 21372151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prolactin decreases expression of Runx2, osteoprotegerin, and RANKL in primary osteoblasts derived from tibiae of adult female rats.
    Charoenphandhu N; Teerapornpuntakit J; Methawasin M; Wongdee K; Thongchote K; Krishnamra N
    Can J Physiol Pharmacol; 2008 May; 86(5):240-8. PubMed ID: 18432284
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The cross-talk between osteoclasts and osteoblasts in response to strontium treatment: involvement of osteoprotegerin.
    Peng S; Liu XS; Huang S; Li Z; Pan H; Zhen W; Luk KD; Guo XE; Lu WW
    Bone; 2011 Dec; 49(6):1290-8. PubMed ID: 21925296
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of nano-hydroxyapatite coating implants on gene expression of osteogenic markers and micro-CT parameters. An in vivo study in diabetic rats.
    de Oliveira PGFP; de Melo Soares MS; Silveira E Souza AMM; Taba M; Palioto DB; Messora MR; Ghiraldini B; Nunes FAS; de Souza SLS
    J Biomed Mater Res A; 2021 May; 109(5):682-694. PubMed ID: 32608088
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The HLA-B27 transgenic rat, a model of spondyloarthritis, has decreased bone mineral density and increased RANKL to osteoprotegerin mRNA ratio.
    Rauner M; Stupphann D; Haas M; Fert I; Glatigny S; Sipos W; Breban M; Pietschmann P
    J Rheumatol; 2009 Jan; 36(1):120-6. PubMed ID: 19040304
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased RANK ligand in bone marrow of orchiectomized rats and prevention of their bone loss by the RANK ligand inhibitor osteoprotegerin.
    Li X; Ominsky MS; Stolina M; Warmington KS; Geng Z; Niu QT; Asuncion FJ; Tan HL; Grisanti M; Dwyer D; Adamu S; Ke HZ; Simonet WS; Kostenuik PJ
    Bone; 2009 Oct; 45(4):669-76. PubMed ID: 19539794
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The prenyl group contributes to activities of phytoestrogen 8-prenynaringenin in enhancing bone formation and inhibiting bone resorption in vitro.
    Ming LG; Lv X; Ma XN; Ge BF; Zhen P; Song P; Zhou J; Ma HP; Xian CJ; Chen KM
    Endocrinology; 2013 Mar; 154(3):1202-14. PubMed ID: 23389955
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.